Format

Send to

Choose Destination
See comment in PubMed Commons below
Acta Histochem. 2014 Jan;116(1):25-31. doi: 10.1016/j.acthis.2013.04.013. Epub 2013 Jun 5.

Best practice for PTEN gene and protein assessment in anatomic pathology.

Author information

1
Department of Obstetrics and Gynecology, School of Medicine of Sao Paulo University, Sao Paulo, SP, Brazil.
2
Research Center, Antonio Prudente Foundation, Hospital A.C. Camargo, Sao Paulo, SP, Brazil.
3
Department of Microbiology, Immunology and Parasitology, UNIFESP, Sao Paulo, Brazil.
4
Department of Anatomic Pathology, Hospital A.C. Camargo, Sao Paulo, SP, Brazil.
5
Research Center, Antonio Prudente Foundation, Hospital A.C. Camargo, Sao Paulo, SP, Brazil; Department of Anatomic Pathology, Hospital A.C. Camargo, Sao Paulo, SP, Brazil. Electronic address: rafael.malagoli@gmail.com.
6
Research Center, Antonio Prudente Foundation, Hospital A.C. Camargo, Sao Paulo, SP, Brazil; Department of Anatomic Pathology, Hospital A.C. Camargo, Sao Paulo, SP, Brazil.

Abstract

There is a lack of standardization of a best practice protocol for Phosphatase and Tensin Homolog (PTEN) assessment by immunohistochemistry in anatomic pathology routine practice. We performed immunohistochemistry for 19 antibodies against PTEN, eleven of which were excluded during the standardization step. Immunohistochemistry of the remaining eight antibodies was performed on a Tissue Microarray containing 55 prostate and 40 renal carcinoma samples. Fluorescent in situ hybridization (FISH) was used as reference standard for immunohistochemistry specificity evaluation. Concerning nuclear staining, polyclonal (Cat#22034-1-AP); 6H2.1 mMAb (Cat#ABM-2052), Y184 RabMAb (Cat#NB110-57441) and 217702 mMAb antibodies presented the highest agreement with fluorescent in situ hybridization (p<0.001 for all) and with regard to cytoplasmic staining, Y184 RabMAb (Cat#NB110-57441); polyclonal (Cat#22034-1-AP) and 217702 mMAb presented the highest agreement (p<0.001 for all). Our results indicate that several commercially available antibodies do not show reliability of sensitivity and specificity for PTEN evaluation and we propose 6H2.1 mMAb (Cat#ABM-2052) as the antibody of choice for laboratory standardization and best practice in clinical routine, which demonstrated excellent sensitivity for both nuclear and cytoplasmic staining, specificity for PTEN by Western blot and good correlation with PTEN status by FISH with regard to nuclear staining.

KEYWORDS:

Fluorescent in situ hybridization; Human; Immunohistochemistry; PTEN; Prostatic neoplasm; Renal cell carcinoma

PMID:
23746542
DOI:
10.1016/j.acthis.2013.04.013
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center